L3VLUP
ProSign in

KRYS · GILD in the 13F filings

Two to four stocks side by side among the 95 tracked managers: who lists them, how that has moved, who bought and sold in a quarter, and which managers hold more than one.

KRYSGILD
Quarter
Q2 2026Q1 2026Q4 2025Q3 2025Q2 2025Q1 2025Q4 2024Q3 2024Q2 2024Q1 2024Q4 2023

Holders over time

Tracked managers listing each stock every quarter, at least, or their combined reported value. A gap is a quarter in which no tracked manager listed it. Click a quarter to compare there.
  • KRYS
  • GILD
010203040202120222023202420252026
Holders and value by quarter
QuarterKRYSGILD
Q3 20204 holders, $52m25 holders, $14.2bn
Q4 20203 holders, $66m27 holders, $13.4bn
Q1 20213 holders, $67m24 holders, $14.5bn
Q2 20212 holders, $28m18 holders, $14.9bn
Q3 20212 holders, $31m20 holders, $16.4bn
Q4 20212 holders, $135m20 holders, $16.8bn
Q1 20221 holders, $114m28 holders, $13.2bn
Q2 20222 holders, $107m26 holders, $13.6bn
Q3 20223 holders, $97m24 holders, $13.3bn
Q4 20223 holders, $59m32 holders, $21.1bn
Q1 20233 holders, $59m27 holders, $21.8bn
Q2 20233 holders, $82m24 holders, $20.7bn
Q3 20235 holders, $143m24 holders, $20.0bn
Q4 20235 holders, $109m22 holders, $21.5bn
Q1 20248 holders, $853m30 holders, $20.3bn
Q2 20246 holders, $1.0bn28 holders, $18.5bn
Q3 20245 holders, $976m29 holders, $24.2bn
Q4 20245 holders, $850m28 holders, $25.9bn
Q1 20255 holders, $993m33 holders, $32.0bn
Q2 20254 holders, $746m27 holders, $30.9bn
Q3 20255 holders, $938m23 holders, $29.4bn
Q4 20257 holders, $1.4bn25 holders, $34.3bn
Q1 20266 holders, $1.5bn25 holders, $38.5bn
Q2 20266 holders, $2.4bn26 holders, $34.2bn
KRYS

Krystal Biotech Inc

Holders
5
Reported value
$938m
Buyers
2
Sellers
1

Breadth +1 among 95 comparable managers.

Pharmaceuticals and biotechnologyBiological productsHealthcare: biopharma and medtech · L3VLUP
GILD

Gilead Sciences Inc

Holders
23
Reported value
$29.4bn
Buyers
9
Sellers
14

Breadth -5 among 95 comparable managers.

Pharmaceuticals and biotechnologyBiological productsHealthcare: biopharma and medtech · L3VLUP

Who holds both, Q3 2025

Among the 24 tracked managers listing any of them. "Only" is about listed positions: a manager may hold the other below its listed range.

Only KRYS (1)

Farallon Capital Management LLC

Only GILD (19)

Acadian Asset Management LLC, AllianceBernstein LP, AQR Capital Management LLC, Arrowstreet Capital LP, Bridgewater Associates LP, Capital Research Global Investors, Citadel Advisors LLC, Dodge & Cox, Holocene Advisors LP, Invesco Ltd, Janus Henderson Group Ltd, Man Group PLC, Marshall Wace LLP, Neuberger Berman Group LLC, Renaissance Technologies LLC, Schonfeld Strategic Advisors LLC, Squarepoint Ops LLC, T. Rowe Price Associates Inc, Wellington Management Group LLP

How much of the picture this is

A 13F is a manager’s long US-listed equity book at a quarter end, filed up to 45 days later. Buyers and sellers count comparable managers (those that filed both quarters) by shares, so a rise in value with no rise in shares is the price. Large books are listed to their largest positions. These are 95 tracked managers, not the institutional market.

Back to the 13F Explorer →